Objectives. We explored sharing nucleic acid amplification testing (NAAT) for detection of Mycobacterium tuberculosis complex (MTBC) and molecular and phenotypic drug susceptibility testing between two state public health tuberculosis (TB) laboratories, and evaluated turnaround times and cost-effectiveness. Results. A total of 182 specimens were referred to the California Lab, and 47 TB cases and 12 drug-resistant cases were identified. The average time for specimen transport was two days, which included one day for processing and packaging in the submitting laboratory. The average turnaround time for NAAT was 0.3 days at the Wisconsin Lab and 3.8 days at the California Lab, including time for specimen transport. Turnaround time for culture-based drug susceptibility testing increased by a median of 16 days when specimens were sent to the California Lab, but MDST results were reported in fewer than four days, a median of 22 days sooner than any culture-based drug susceptibility testing results.
Tuberculosis (TB) remains a significant global public health threat, with an estimated 9.0 million new cases in 2013. 1 The year 2013 marked the 21st year of decline in TB cases, with 9,582 cases reported; 18 states had annual caseloads #50. 2 This decline was partially due to advances in laboratory technologies that allowed for rapid detection of TB and drug resistance, which can result in a more timely intervention and interruption of further transmissions.
TB laboratories currently perform a complicated mix of conventional and molecular methods to offer rapid, accurate, and sensitive diagnosis, identification, and susceptibility test results. In areas where TB incidence is low, offering a full spectrum of TB laboratory services in the face of ever-decreasing test volumes presents a challenge. Maintaining proficiency and quality for low-volume tests is both difficult and costprohibitive. Ongoing budgetary concerns and retirement of experienced laboratory professionals further contribute to this struggle. Both regionalization of laboratory services and collaboration among laboratories to share testing have the potential to maintain quality laboratory testing and control expenses. Laboratories are hesitant to explore these opportunities, as many aspects of shared laboratory services have not been fully examined. To systematically evaluate and document the challenges and successes associated with shared services, the Association of Public Health Laboratories, in collaboration with the Centers for Disease Control and Prevention Division of Tuberculosis Elimination, offered a one-time competitive funding opportunity for public health laboratories to pilot alternative models for TB testing service delivery.
The California-Wisconsin project involved implementing a shared services model in which a public health laboratory from a low-TB-incidence state, the Wisconsin State Laboratory of Hygiene (hereinafter referred to as "Wisconsin Lab"), submitted specimens to a high-volume laboratory, the Microbial Diseases Laboratory (hereinafter referred to as "California Lab") of the California Department of Public Health. Testing performed at the California Lab included nucleic acid amplification testing (NAAT) for direct detection of Mycobacterium tuberculosis complex (MTBC) from sediments and cultures by pyrosequencing, molecular drug susceptibility testing (MDST) for sediments and cultures using pyrosequencing, and culture-based drug susceptibility testing (CDST) by the BACTEC TM MGIT TM 960 (hereinafter referred to as MGIT) (Becton Dickinson, Sparks, Maryland). The Wisconsin Lab maintained testing capabilities during the study; testing was performed in parallel to compare cost and turnaround times, and to assess the effect of shared services. The three objectives of the study were to (1) assess feasibility and consequences of referring smear-positive sediments to a reference laboratory for NAAT, (2) assess the utility of universal referral of decontaminated sediments and cultures for rapid MDST, (3) and assess feasibility, consequences, and cost of referring first-and secondline CDST to a reference laboratory.
METHODS

Study design
Clinical specimens were decontaminated and concentrated at the Wisconsin Lab using standard procedures to yield sediments ( Figure) . 3 Specimens were also processed at other Wisconsin clinical laboratories, and sediments were sent to the Wisconsin Lab for NAAT. The Wisconsin Lab performed NAAT to detect MTBC using a laboratory-developed real-time Taqman TB polymerase chain reaction assay 4 on initial smear-positive sediments from patients for whom a TB diagnosis was being considered. 5 An aliquot of each smear-positive sediment was forwarded to the California Lab for pyrosequencing. The pyrosequencing assay performed at the California Lab is both a NAAT for MTBC detection and an MDST assay for detection of mutations that confer resistance to isoniazid, rifampin, quinolones, and the injectable drugs amikacin, capreomycin, and kanamycin 6 ( Table 1) . The Wisconsin Lab also sent initial MTBC-positive cultures (NAAT-negative or NAAT not performed) to the California Lab for pyrosequencing.
The California Lab performed CDST using MGIT for recommended TB first-line drugs 7 (Table 1) . For the first five months of the study (September 1, 2012, to January 31, 2013), the California Lab set up CDST using growth from MGIT seed tubes inoculated from residual NAAT-positive sediments, but encountered contamination and viability issues with these specimens. For the last four months of the study, the Wisconsin Lab submitted smear-positive sediments for NAAT and MDST, and subsequently submitted MTBC-positive broth culture from the same patient for CDST.
If no mutations were detected by MDST, the California Lab set up CDST for primary drugs only. If mutations associated with resistance to isoniazid or rifampin were detected, expanded CDST for primary drugs including two concentrations of isoniazid (0.1 and 0.4 micrograms per milliliter) and second-line drugs (amikacin, capreomycin, moxifloxacin, and ethionamide) was set up. 8 The Wisconsin Lab performed parallel first-line testing using MGIT. The California Lab performed pyrosequencing within one working day of sample receipt and set up CDST one or two sediments. An aliquot of each sediment was forwarded to MDL for pyrosequencing to detect MTBC and mutations that confer resistance. WSLH set up culture for primary clinical specimens and sent aliquots of initial MTBC-positive cultures (NAAT-negative or NAAT not performed) to MDL for pyrosequencing. Tuberculosis first-line culture-based DST was performed in parallel at the two laboratories. Second-line culture-based DST was performed at MDL when indicated. 10 Category A (infectious substance) shippers were used for MTBC-positive broth cultures, and category B (diagnostic specimen) 95 kilopascal pressure bags and overpacks were used for smear-positive sediments. Transport times were calculated in calendar days. Packages were picked up by FedEx or UPS mid-afternoon at the Wisconsin Lab with expected delivery to the California Lab the following morning before 10 a.m. We did not evaluate the difference in transport time between the two courier services.
Reporting results
The California Lab generated official reports and faxed them to the Wisconsin Lab. The Wisconsin Lab forwarded preliminary and final results to the Wisconsin TB Program, health-care providers, and appropriate local Wisconsin public health departments by telephone, fax, and the Wisconsin Electronic Disease Surveillance System.
Data collection
The following data were collected for each specimen: date of receipt of original specimen or isolate at the Wisconsin Lab, specimen type, material sent to the California Lab (e.g., split sediment, broth culture), date of identification of MTBC at the Wisconsin Lab, date specimen or culture shipped to the California Lab, date of receipt at the California Lab, shipping method used, date testing performed or set up, date preliminary and final results reported, results reported by the California Lab, and results reported by the Wisconsin Lab. Turnaround times calculated in calendar days included time between specimen receipt at the Wisconsin Lab and shipment to the California Lab (for specimen processing and packaging), courier transport time between the Wisconsin Lab and the California Lab, and testing turnaround times from date of receipt at the California Lab and date of receipt at the Wisconsin Lab. We used the t-test to assess differences in mean turnaround times for NAAT and CDST between the two laboratories. Testing costs at the California Lab were calculated by compiling material and labor costs. Testing costs at the Wisconsin Lab were calculated using its fee schedule.
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RESULTS
Test volume and specimen transport time
In 2011, before the study, California Lab test volumes for NAAT, MDST, and CDST were 536, 195, and 536 specimens, respectively, and Wisconsin Lab test volumes for NAAT and CDST were 175 (smear positive) and 69, respectively. During the nine-month pilot study, a total of 182 specimens from 162 patients were referred for testing from the Wisconsin Lab to the California Lab in 90 shipments. On average, 18 smear-positive NAATs and 4.5 CDSTs were referred to the California Lab per month during the study period; these averages were similar to normal testing volumes for the Wisconsin Lab and added approximately 32% more specimens for NAAT and 13% more specimens for CDST to the California Lab workload. In the last four months of the study, both smear-positive sediments and MTBC-positive broths from 20 patients were sent to the California Lab. Pyrosequencing (NAAT and MDST) at the California Lab was performed for all 162 patients and CDST was performed on 41 specimens ( Table 2 ).
The average time between receipt at the Wisconsin Lab and shipment to the California Lab was 0.9 days (range: 0-5 calendar days); this time was used for specimen processing and packaging. The average transport time was 1.1 calendar days (range: 1-5). The total average time from receipt at the Wisconsin Lab to receipt at the California Lab was 2.0 days, with specimen processing, packaging, and courier transport combined.
Referral of sediments for NAAT and MDST
Of 182 total specimens, 140 were smear-positive sediments referred to the California Lab for pyrosequencing (NAAT for detection of MTBC and MDST). NAAT was performed in parallel at the Wisconsin Lab for 135 specimens by real-time polymerase chain reaction. Among the 140 sediments, 28 were NAAT-positive and culture-positive for MTBC (20%). The sensitivity of the Wisconsin Lab real-time polymerase chain reaction assay and MDL pyrosequencing assay for detection of MTBC was 78.6% (22/28) and 92.9% (26/28), respectively. The average turnaround time for NAAT at the Wisconsin Lab (0.3 days; range: 0-4 days) was significantly faster (p,0.001) than that for pyrosequencing (both NAAT and MDST) at the California Lab (3.8 days; range: 3-11 days) ( Table 2) .
Of the 182 specimens, 47 new TB cases were identified. A total of 28 cases (60%) were rapidly identified by NAAT and 19 cases (smear-negative, NAAT not performed at the Wisconsin Lab) were identified after MTBC growth in culture. All 47 new TB cases had MDST performed at the California Lab either on the smear-positive sediment or on culture growth. Three cases (6%) were identified as new multidrug-resistant TB patients (i.e., resistant to at least isoniazid and rifampin) and nine patients (19%) were resistant to isoniazid alone. The 12 new drug-resistant TB patients were rapidly detected by MDST in an average of 3.8 days. On average, MDST results from the California Lab were reported 22 days before Wisconsin Lab inhouse first-line CDST results were available (Table 2) .
TB first-and second-line CDST Of the 47 newly identified TB cases, first-line CDST was performed in parallel on 41 isolates and secondline CDST was performed at the California Lab on 12 isolates. The median turnaround time for reporting conventional TB first-line CDST at the Wisconsin Lab (26 days; range: 14-59 days) was significantly faster (p,0.001) than when referred to the California Lab (42 days; range: 21-114). Of the 41 specimens for which the California Lab performed CDST, 17 (41.5%) grew poorly in MGIT after transport and required additional subculture to solid media to obtain adequate growth for CDST. The California Lab was unable to perform DST for six (12.8%) TB cases due to contamination or culture viability issues. The California Lab's median CDST turnaround time improved from 49 days to 37 days in the last four months of the study, when only MTBC-positive culture growth was used as seed tube inoculum. The median turnaround time for conventional TB second-line CDST at the California Lab was 41.5 days (range: 27-115 days) ( Table 2) .
Costs for shipping and referral testing
approximately $50.00 per package or $4,500.00 for the entire study ( Table 3 ). The total average cost for shipping one specimen (Category A and Category B packages combined) was $99.54, including materials, courier service, and labor for packaging.
Costs for referral testing at the California Lab during the nine-month study period totaled $45,341.60, which included supplies and labor for shipping, courier services, and all testing performed ( Table 3 ). The cost for full work-up of a single smear-positive MTBC-positive clinical specimen was $482.00 at the Wisconsin Lab (including NAAT and TB first-line CDST) and $676.54 at the California Lab (including NAAT, MDST, TB firstand second-line CDST, and average shipping costs).
DISCUSSION
The first objective of this pilot project was to assess the feasibility and consequences of referring smear-positive sediments to a reference laboratory to detect MTBC by NAAT. NAAT is one of the most important diagnostic tools for direct detection of MTBC from TB suspects, and rapid turnaround times are crucial. Documented benefits and cost savings are associated with rapid diagnosis of TB or exclusion of TB as the cause for disease, 12 and effective patient treatment, infection control, and contact investigation decisions are often based on NAAT results. [13] [14] [15] During the nine-month pilot, 140 smear-positive sediments were referred to the California Lab, and 135 of these sediments were tested in parallel at the Wisconsin Lab. Between the two laboratories, 28 new TB patients were rapidly Our study found that specimen preparation and transport between submitting and reference laboratories resulted in a significant increase in turnaround time. During the study, the average time for specimen packaging and preparation was 0.9 days and the average time for courier transport was 1.1 days. With two days spent en route to the reference laboratory, the U.S. Department of Health and Human Services Healthy People 2020 goal 16 of detecting TB by NAAT within 48 hours could not be met. Electronic result reporting was not set up between the Wisconsin Lab and the California Lab during the study period. It is possible that real-time transmission of results between laboratory information systems could have improved turnaround times, although reports were faxed from the California Lab as soon as they were available.
The Wisconsin TB Program relies heavily on NAAT testing for diagnosis and management of the most infectious new TB cases. An increase in NAAT turnaround time from 0.3 to 4.0 days would likely lead to longer stays in respiratory isolation and delayed treatment initiation for Wisconsin TB patients. Referral of specimens for NAAT is necessary if laboratories do not have the capability to perform this essential testing in-house. Even NAAT results that do not meet the Healthy People 2020 goal would be reported before culture-based detection and, therefore, would still be of value to health-care providers. Additionally, the California Lab was able to offer a NAAT with improved sensitivity for better TB detection. Assay performance is an important factor when evaluating reference testing and weighing potential increases in turnaround time. The second objective of the pilot program was to assess the utility of universal referral of sediments and cultures for rapid MDST by pyrosequencing at the California Lab. Although Wisconsin is considered a low-incidence state, with ,1.0 case of TB per 100,000 population, 17 drug resistance is prevalent in foreignborn patients from Laos, Thailand, India, or China who immigrate to Wisconsin. Prior to the study, only specimens from patients with documented risk factors for multidrug-resistant TB were referred to the Centers for Disease Control and Prevention Molecular Detection of Drug Resistance Program. 18 During the study, the California Lab provided MDST results for all MTBCpositive specimens and identified 12 drug-resistant cases. MDST results were available 22 days ahead of in-house conventional TB first-line DST results.
The Wisconsin TB program used MDST results as the first indication of whether or not standard TB therapy would be effective. In cases where patients were predicted to be high-level isoniazid resistant, isoniazid was dropped from the regimen and moxifloxacin was considered. In cases where both isoniazid and rifampin resistance were predicted, patients were either treated empirically or left untreated until CDST results were available. Although difficult to quantify, the benefits of molecular testing far outweighed the cost. Twelve drug-resistant patients were placed on optimal therapy or taken off potentially ineffective therapy within days, leading to more rapid clinical improvement and less potential for transmission. These therapy decisions would have been made weeks later if health-care providers had relied on CDST alone.
Although useful for management of both drug-resistant and susceptible patients, universal MDST is likely not sustainable due to cost. Both the State of California and the Centers for Disease Control and Prevention Molecular Detection of Drug Resistance Program have established criteria to perform MDST for patients with risk factors for drug resistance. 18 In this study, all 12 drug-resistant cases from Wisconsin were foreign-born and would have met criteria for referral MDST testing. A screened referral approach that includes molecular predictions for at least isoniazid and rifampin resistance is a clinically sensible, cost-effective way to implement MDST. In cases where molecular testing indicates both isoniazid and rifampin resistance, TB case managers require a full panel of molecular testing that includes analysis of embB and pncA for the other TB first-line drugs (ethambutol and pyrazinamide, respectively), gyrA (for fluoroquinolones), and rrs (for injectables) before starting multidrug-resistant TB therapy.
The third objective was to assess feasibility and consequences of referring first-and second-line CDST to a reference laboratory. During the study, the California Lab performed first-line CDST for 41 specimens, with an overall median turnaround time of 42 days. Referral led to a 16-day median delay in receiving results compared with in-house testing at the Wisconsin Lab.
At the beginning of the study, residual MTBCpositive sediments were used to inoculate MGIT seed tubes for CDST at the California Lab. For the last four months of the study, in an attempt to address lengthened turnaround times, the submission protocol was altered. The Wisconsin Lab submitted additional MTBC-positive broth to serve as inoculum for MGIT seed tubes for each NAAT-positive sediment. Although submission of broth improved the California Lab's CDST turnaround time by 12 days, difficulties were encountered with both types of inoculum. Organisms in the sediment were potentially exposed to residual sodium hydroxide for a lengthy period during transport and were often slow-growing, nonviable, or contaminated. Small broth aliquots did not contain enough organisms and often required subculture to obtain adequate growth. The California Lab now requests submission of an entire MTBC-positive MGIT tube (approximately 8 milliliters of broth growth) for CDST at the National Reference Center.
Although referral turnaround times for first-line CDST were longer than the recommended goal of 28 days, 19, 20 the Wisconsin TB program did not find the longer turnaround times to be as consequential because molecular results were rapidly available. Except in cases of suspected multidrug resistance, therapy could be initiated based on molecular results without waiting for CDST.
In many reference laboratories, TB second-line CDST is performed using a traditional agar proportion method with an effective turnaround time of six weeks: three weeks for adequate growth on solid media and three weeks for the assay itself. Often, second-line CDST is not initiated until resistance is discovered by conventional first-line CDST, causing additional delays. Applying a proactive testing algorithm, the California Lab set up second-line CDST as soon as resistance was indicated by MDST using a laboratory-developed MGIT assay for four second-line drugs. The California Lab obtained second-line CDST turnaround times similar to those for first-line CDST (median: 41.5 days). Additional CDST for drugs such as para-aminosalicylic acid, cycloserine, and rifabutin may be required for therapeutic decisions for certain multidrug-resistant or extensively drug-resistant cases.
CONCLUSION
Our study demonstrated both advantages and disadvantages associated with sharing TB laboratory services. The most important advantage of referral testing was the availability of specialized testing such as MDST and TB second-line CDST, which were beneficial to Wisconsin TB patients but not available at the Wisconsin Lab. Molecular and other laboratory-developed assays are technically challenging; test implementation and maintaining staff proficiency would be nearly impossible in low-incidence, low-volume settings. Laboratories must consider sending specimens to a reference laboratory or center of excellence to receive specialized testing that is crucial for patient management.
We also identified disadvantages associated with sharing laboratory services. Referral of specimens led to significant delays in NAAT and CDST. Our study found that NAAT was not as conducive to referral as other mycobacteriology testing because of the very short turnaround times required. Achieving the Healthy People 2020 goal for identification of new TB patients within 48 hours using NAAT was not possible for most specimens during this pilot. Delays in NAAT and CDST were partially due to referral and transport times. Additional DST delays were due to detrimental effects of shipping that left organisms nonviable or specimens contaminated with endogenous flora. Effects of delays in CDST reports were partially mitigated by rapid molecular results. A final obstacle for referral testing was cost. Data from this study demonstrated that referral testing was more expensive than in-house testing. Yet, the added expense of referral testing came with greater value, as important specialized testing was available only through the reference laboratory.
A compelling finding in our study was that effective communication was necessary for a shared services testing algorithm to function optimally. Through communications such as these, the Wisconsin Lab altered the type of specimen submitted for CDST to improve turnaround times in the latter part of the study. Submitting laboratories must also communicate with health-care providers and TB control partners to ensure that testing needs and turnaround time requirements are met by the reference laboratory. At a time when mycobacteriology laboratories are experiencing staffing shortages and funding difficulties, reference laboratories can offer testing that may not otherwise be available. Molecular and specialized assays offered at reference laboratories are becoming the standard of testing, and results are indispensable when TB programs and health-care providers are making critical patient management decisions. The benefits of referral testing often outweigh the associated costs and delays in results.
